Page last updated: 2024-12-07

nipecotic acid ethyl ester

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Nipecotic acid ethyl ester is a synthetic compound that acts as a potent inhibitor of the enzyme choline acetyltransferase (ChAT). ChAT is responsible for the synthesis of acetylcholine, a neurotransmitter that plays a crucial role in various physiological processes, including muscle contraction, memory, and learning. Nipecotic acid ethyl ester's inhibitory effect on ChAT leads to a decrease in acetylcholine levels, making it a valuable tool for studying the role of acetylcholine in various biological systems. The compound has been used in research to investigate the mechanisms of cholinergic transmission and to explore potential therapeutic applications in conditions such as Alzheimer's disease and Parkinson's disease.'

nipecotic acid ethyl ester: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID98969
CHEMBL ID348637
SCHEMBL ID132090
MeSH IDM0114631

Synonyms (67)

Synonym
einecs 276-211-9
ethyl piperidine-3-carboxylate (+-)-
ethyl nipecotate
nsc-158451
5006-62-2
nsc158451
ethyl nipecotate, 96%
STK263694
ethyl piperidine-3-carboxylate
71962-74-8
CHEMBL348637
piperidine-3-carboxylic acid ethyl ester
xiwbsounzwsfku-uhfffaoysa-
inchi=1/c8h15no2/c1-2-11-8(10)7-4-3-5-9-6-7/h7,9h,2-6h2,1h3
ethyl 3-piperidinecarboxylate
E0584
nipecotic acid ethyl ester
3-piperidinecarboxylic acid ethyl ester
AKOS000119413
A5099
(r)-ethyl piperidine-3-carboxylate;ethyl (r)-3-piperidinecarboxylate
A827957
einecs 225-681-3
nsc 158451
3-(ethoxycarbonyl)piperidine
FT-0630240
FT-0626273
FT-0626214
FT-0639395
PB32324
PB24683
SCHEMBL132090
AKOS016037130
J-502491
PS-5077
3-piperidinecarboxylic acid, ethyl ester, (3r)-
(rac)-nipecotic acid ethyl ester
(+ -)-ethylnipecotate
ethylpiperidine-3-carboxylate
(+)-ethyl nipecotate
3-ethoxycarbonylpiperidin
ethylnipecotate
piperdine-3-carboxylic acid ethyl ester
ethyl 3-piperidine-carboxylate
(+/-)-ethyl piperidine-3-carboxylate
racemic ethyl nipecotate
ethyl (+) nipecotate
ethyl 3-piperidylcarboxylate
(+/-)-ethyl nipecotate
(+/-) ethylnipecotate
a-ethyl nipecotate
ethyl (+/-) nipecotate
W-105989
STR04590
3-piperidinecarboxylic acid, ethyl ester, (.+/-.)-
ethyl 3-piperidinecarboxylate #
AC-22462
mfcd00005991
F2190-0331
CS-B1309
( inverted exclamation marka)-3-piperidinecarboxylic acid ethyl ester
BBL020088
SB20053
4,5,6,7-tetrahydro-3-(phenylmethyl)-(s)-3h-imidazo[4,5-c]pyridine-6-carboxylicacid
DTXSID301316669
3-piperidinecarboxylic acid, ethyl ester, (a+/-)-
EN300-20335
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID183074Inhibition of GABA uptake from rat diencephalon-midbrain at 100 uM concentration1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Orally active and potent inhibitors of gamma-aminobutyric acid uptake.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (44.44)18.7374
1990's1 (11.11)18.2507
2000's3 (33.33)29.6817
2010's1 (11.11)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.25 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]